Catheter ablation of atrial fibrillation in the elderly: Where do we stand?

Cardiology Journal

Volumn 16, Issue 2, 2009, Pages 113-120

  Traub, Darren ^a   Daubert, James P ^a   McNitt, Scott ^a   Zareba, Wojciech ^a   Hall, Burr ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Catheter ablation; Elderly patients

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SOTALOL; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; CATHETER ABLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; SINUS RHYTHM; AGE; ELECTROCARDIOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 66349112683     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Kamanth S, Lip GYH. Atrial fibrillation in the elderly: Anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol, 2002; 11: 357-364.
2. Lip GYH, Kakar P, Watson T. Atrial fibrillation - the growing epidemic. Heart, 2007; 93: 542-543.
3. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on projections for future prevelance. Circulation, 2006; 114: 119-125.
4. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults. National Implications for rhythm management and stroke prevention: the An Ticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285: 2370-2375.
5. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol, 2006; 48: e149-e246.
6. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med, 1995; 155: 469-473.
7. Berry C, Rae A, Taylor J, Brady AJ. Atrial fibrillation in the elderly. Br J Cardiol, 2003; 10: 373-378.
8. Dayer MB, Hardman SMC. Special problems with antiarrhythmic drugs in the elderly: Safety, tolerability, and efficacy. Am J Geriatr Cardiol, 2002; 11: 370-375.
9. Curtis AB, Rich MW. Atrial fibrillation in the elderly: Mechanisms and management. Heart Rhythm, 2007; 4: 1577-1599.
10. Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med, 2007; 120: 481-487.
11. Pappone C, Augello G, MD, Sala S et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. J Am Coll Cardiol, 2006; 48: 2340-2347.
12. Oral H, Pappone C, Chugh A et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation volume. NEJM, 2006; 354: 934-941.
13. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA, 2005; 293: 2634-2640.
14. Traub D, Ganz L. Implantable cardioverter-defibrillators for secondary prevention: Is it worth it in the elderly? AJGC, 2006; 15: 93-99.
15. Hsieh MH, Tai CT, Lee SH et al. Catheter ablation for atrial fibrillation versus atrioventricular junctional ablation plus pacing for elderly patients with medically refractory paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol, 2005; 16: 457-461.
16. Khan MN, Jais P, Cummings J et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med, 359; 17: 1778-1885.
17. Corrado A, Patel D, Riedlbauchova L et al. Efficacy, safety and outcome of atrial fibrillation ablation in septuagenarians. J Cardiovasc Electrophysiol, 2008; 19:1-5.
18. Zado E, Callans DJ, Riley M, et al. Long-term efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol, 2008; 19: 621-626.
19. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation, 2005; 111: 1100-1105.
20. Bertaglia E, Zoppo F, Tondo C et al. Early complications of pulmonary vein catheter ablation for atrial fibrillation: A multicenter prospective registry on procedural safety. Heart Rhythm, 2007; 4: 1265-1271.
21. Gerstenfeld EP, Callans D, Dixit S et al. Characteristics of patients undergoing atrial fibrillation ablation: Trends over a seven-year period 1999-2005. J Cardiovasc Electrophysiol, 2007; 18: 23-38.
22. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 2002; 347: 1825-1833.
23. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 2004; 109: 1509-1513.
24. Pederson OD, Bagger H, Keller N et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation, 2001; 104: 292-296.
25. Pandit SV, Jalife J. Aging and atrial fibrillation research: Where we are and where we should go. Heart Rhythm, 2007; 4: 186-187.
26. Anyukhovsky EP, Sosunov EA, Chandra P et al. Age-associated changes in electrophysiologic remodeling: A potential contributor to initiation of atrial fibrillation. Cardiovasc Res, 2005; 66: 353-363.
27. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA, 2005; 293: 2634-2640.
28. Stabile G, Bertaglia E, Senatore G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: A prospective, mulit-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J, 2006; 27: 216-221.
29. Pappone C, Augello G, Sala S et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF study. J Am Coll Cardiol, 2006; 48: 2340-2347.
30. Jaïs P, Cauchemez B, Macle L et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: The A4 study. Circulation, 2008; 118: 2498-2505.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results of the National Registry of Atrial Fibrillation. JAMA, 2001; 285: 2864-2870.